{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:44:10Z","timestamp":1762098250347,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.healun.2005.11.438","type":"journal-article","created":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T15:09:32Z","timestamp":1141225772000},"page":"469-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Preliminary Experience With Bosentan as Initial Therapy in Childhood Idiopathic Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"25","author":[{"given":"Catherine M.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Penny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Cochrane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle L.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2005.11.438_bib1","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.CIR.99.9.1197","article-title":"Vasodilator therapy for primary pulmonary hypertension in children","volume":"99","author":"Barst","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2005.11.438_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D\u2019Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.healun.2005.11.438_bib3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0735-1097(94)00391-3","article-title":"Primary pulmonary hypertension in children","volume":"25","author":"Sandoval","year":"1995","journal-title":"J Am Coll Cardiol"},{"issue":"12 Suppl S","key":"10.1016\/j.healun.2005.11.438_bib4","doi-asserted-by":"crossref","first-page":"81S","DOI":"10.1016\/j.jacc.2004.02.038","article-title":"Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"43","author":"Galie","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2005.11.438_bib5","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s001090050363","article-title":"Endothelin antagonism with bosentan","volume":"77","author":"Roux","year":"1999","journal-title":"J Mol Med"},{"key":"10.1016\/j.healun.2005.11.438_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ppul.20051","article-title":"Pulmonary arterial hypertension in children","volume":"38","author":"Rosenzweig","year":"2004","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.healun.2005.11.438_bib7","first-page":"A48","article-title":"Relation of endothelin-1 to survival in patients with primary pulmonary hypertension","volume":"26","author":"Galie","year":"1996","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.healun.2005.11.438_bib8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2005.11.438_bib9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.healun.2005.11.438_bib10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2005.11.438_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","article-title":"Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension","volume":"73","author":"Barst","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.healun.2005.11.438_bib12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension","volume":"43","author":"Sastry","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2005.11.438_bib13","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.0000099502.17776.C2","article-title":"Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension","volume":"108","author":"Michelakis","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2005.11.438_bib14","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2005.11.438_bib15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1183\/09031936.04.00051104","article-title":"Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension","volume":"24","author":"Hoeper","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2005.11.438_bib16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1378\/chest.89.4.497","article-title":"Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension","volume":"89","author":"Barst","year":"1986","journal-title":"Chest"},{"key":"10.1016\/j.healun.2005.11.438_bib17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/01.CIR.0000138104.83366.E9","article-title":"Outcomes in children with idiopathic pulmonary arterial hypertension","volume":"110","author":"Yung","year":"2004","journal-title":"Circulation"},{"year":"2003","series-title":"Stata Statistical Software. Release 8.0","key":"10.1016\/j.healun.2005.11.438_bib18"},{"key":"10.1016\/j.healun.2005.11.438_bib19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.healun.2005.11.438_bib20","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2005.11.438_bib21","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.healun.2005.11.438_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1378\/chest.124.1.247","article-title":"Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension","volume":"124","author":"Sitbon","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.healun.2005.11.438_bib23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2005.01.066","article-title":"Effects of long-term Bosentan in Children with Pulmonary Arterial Hypertension","volume":"46","author":"Rosenzweig","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2005.11.438_bib24","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1161\/01.CIR.99.25.3266","article-title":"Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension","volume":"99","author":"Langleben","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2005.11.438_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2005.11.438_bib26","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2005.11.438_bib27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.amjcard.2003.12.031","article-title":"Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan","volume":"93","author":"Ivy","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.healun.2005.11.438_bib28","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.healun.2003.09.024","article-title":"Sildenafil for pulmonary hypertension after heart transplantation","volume":"23","author":"Kulkarni","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2005.11.438_bib29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.healun.2004.01.017","article-title":"Novel use of sildenafil in the treatment of portopulmonary hypertension","volume":"24","author":"Chua","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2005.11.438_bib30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2005.11.438_bib31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2005.11.438_bib32","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1378\/chest.112.3.714","article-title":"The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension","volume":"112","author":"Frank","year":"1997","journal-title":"Chest"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249805013306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249805013306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:12:54Z","timestamp":1760947974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249805013306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S1053249805013306"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2005.11.438","relation":{},"ISSN":["1053-2498"],"issn-type":[{"type":"print","value":"1053-2498"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preliminary Experience With Bosentan as Initial Therapy in Childhood Idiopathic Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2005.11.438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}